Alto Neuroscience, Inc. (NYSE: ANRO) announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (PIPE) for gross proceeds of approximately $50 million, before deducting offering expenses.
The PIPE will provide the company with additional capital to support its ongoing development programs, including the ALTO‑207 fixed‑dose combination for treatment‑resistant depression, and to maintain its cash runway into 2028.
The announcement confirms that the company will use the proceeds to fund clinical development activities and related operational needs, reinforcing its liquidity position and enabling continued progress on its precision psychiatry platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.